Management of Hepatic Sarcoidosis: A Retrospective Analysis of Patients at a University Hospital
Authors:
Open Access
- 1 September 2025
- journal article
- Published by Convin SA in Mediterranean Journal of Rheumatology
- Vol. 36 (3) , 423-427
Abstract
Objective: To explore efficacy of medications, namely steroids, ursodeoxycholic acid (UDC), methotrexate (MTX), azathioprine, mycophenolate mofetil (MMF), and infliximab in the treatment of hepatic sarcoidosis (HS). Methods: We searched for the patients using ICD codes for sarcoidosis (ICD-10: D86) and granulomatous hepatitis (ICD-10: K75.3) at Louisiana State University, Shreveport, and generated 150 unique medical record numbers. We retrospectively reviewed notes, labs, imaging, and medications, and used descriptive statistics to calculate percentages. Results: 47 patients had a diagnosis of HS. 72% of patients had ALP elevation of >200. 36 (76%) patients received steroids, 20 (42%) had MTX, 5 (10%) had azathioprine, 5 (10%) had rituximab, 12 (25%) had infliximab, 3 (6%) had UDC, 21 (44%) had MMF. 12 patients received a combination of prednisone with either MTX, azathioprine, MMF, infliximab, or rituximab. Treatment response was measured based on ALP improvement. 55% of patients responded to prednisone, 45% to MTX, 40% to azathioprine, 60% to rituximab, 66% to infliximab, 47% to MMF, and 30% to UDC. Conclusion: Majority of the patients presented with ALP elevation of >200. Liver biopsy was performed in only 27% of the patients. Despite being one of the recommended initial therapies, UDC was used in only 3% of patients. Steroids were most commonly used. Among all the steroid-sparing agents, infliximab showed the best efficacy. Similarly, MTX showed improvement, but it was generally avoided due to the risk of hepatotoxicity. Azathioprine, MMF, and rituximab were used either in combination or as sole therapies and have shown improvement in ALP. Cite this article as: Sondhi M, Hasan S, Vadlamudi K, Bhuiyan MAN, Ali A, Muutu T, Hayat S, Umer S, Muzaffar K. Management of Hepatic Sarcoidosis: A Retrospective Analysis of Patients at a University Hospital. Mediterr J Rheumatol 2025;36(3):423-427. Article Submitted: 11 Nov 2024; Revised Form: 3 Apr 2025; Article Accepted: 23 Apr 2025; Available Online: 17 Jul 2025 This work is licensed under a Creative Commons Attribution 4.0 International License. ©2025 The Author(s). https://doi.org/10.31138/mjr.111124.thrKeywords
This publication has 17 references indexed in Scilit:
- Hepatic Sarcoidosis Presenting as Portal Hypertension and Liver Cirrhosis: Case Report and Review of the LiteratureCase Reports in Gastroenterology, 2012
- Granulomatous liver diseases: A reviewJournal of the Formosan Medical Association, 2012
- Liver-test abnormalities in sarcoidosisEuropean Journal of Gastroenterology & Hepatology, 2012
- Sarcoidosis in Black Women in the United StatesChest, 2011
- Extrapulmonary SarcoidosisSeminars in Respiratory and Critical Care Medicine, 2007
- Natural history of hepatic sarcoidosis and its response to treatmentEuropean Journal of Gastroenterology & Hepatology, 2006
- Tumor necrosis factor inhibition as a novel treatment for refractory sarcoidosisArthritis Care & Research, 2005
- MRI of Hepatic Sarcoidosis: Large Confluent Lesions Mimicking MalignancyAmerican Journal of Roentgenology, 2004
- CT Patterns of Nodular Hepatic and Splenic Sarcoidosis: A Review of the LiteratureJournal of Computer Assisted Tomography, 1997
- Hepatic sarcoidosis. Clinicopathologic features in 100 patients.1993